Miromatrix Medical Inc. a life sciences company. The Company is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreases. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. The Company's product pipeline includes miroliver, mirokidney, miroheart, mirolung and miropancreas.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)